IGF-1 (insulin-like growth factor 1) is not a synthetic peptide developed in a lab — it is a hormone your body produces naturally, primarily in the liver, in response to growth hormone (GH) stimulation from the pituitary gland. Named for its structural similarity to insulin, IGF-1 is the key downstream mediator of growth hormone's anabolic effects on virtually every tissue in the body.
IGF-1 levels peak during puberty and adolescence — the period of most rapid growth — and then decline gradually throughout adulthood. By age 60, typical IGF-1 levels are roughly 40% of what they were at age 20. This age-related decline runs parallel to the loss of muscle mass, bone density, and tissue repair capacity associated with ageing, making IGF-1 one of the most studied targets in longevity research.
The performance and biohacking community's interest is in exogenous IGF-1 — specifically engineered analogues that are more stable or potent than native IGF-1 for injection. The two most common are IGF-1 LR3 (long-acting, 20-30 hour half-life, systemic effects) and IGF-1 DES (short-acting, ~20 minutes, site-specific effects). Both are research chemicals, not approved drugs, and both are banned by WADA.
IGF-1 works by binding to the IGF-1 receptor (IGF1R) — a tyrosine kinase receptor expressed in skeletal muscle, bone, connective tissue, and virtually every organ. Receptor activation triggers a cascade that is essentially the master switch for anabolic processes.
The Cancer Question — The Most Important Thing to Understand About IGF-1: IGF-1 promotes cell growth, division, and survival — in all cells, including cancer cells. Chronically elevated IGF-1 levels have been epidemiologically associated with increased risk of prostate, breast, colorectal, and lung cancers. This is not a theoretical concern: it is a documented signal across multiple large population studies. The IGF-1 signalling pathway (PI3K/Akt/mTOR) is one of the most frequently dysregulated pathways in cancer. Anyone with a personal or family history of cancer should consider IGF-1 use extremely carefully. The same mTOR activation that builds muscle is the activation that cancer cells exploit.
IGF-1 occupies the top tier of the performance peptide hierarchy — more powerful than GH secretagogues, used in combination with anabolic steroids and HGH in advanced bodybuilding and competitive physique circuits. It is not a beginner compound and is not primarily used for health optimisation — it is a high-risk, high-reward anabolic agent. The community using it tends to be fully aware of the risks and have typically cycled multiple compounds first.
IGF-1 is a powerful anabolic hormone — its synergies amplify muscle protein synthesis while managing the significant risks it carries. Nutrition and exercise protocols are not optional additions; they are essential safety requirements.
Disclaimer: These recommendations are educational and based on the known mechanisms of each compound. Individual responses vary. Consult a qualified healthcare provider before changing your supplement or exercise regimen, particularly when using experimental peptides.
The compounds and practices below have evidence supporting synergy with this peptide — either working on the same biological pathway, providing essential co-factors, or creating the physiological conditions that amplify the peptide's effects. Evidence ratings reflect the strength of the supporting science.
IGF-1 sits at a unique intersection in this book: it is a genuinely important endogenous hormone with real anabolic function, documented clinical relevance in deficiency states, and legitimate anti-ageing interest — and simultaneously one of the higher-risk compounds in community use, with a documented cancer-promoting signal and serious acute hypoglycemia risk.
The Laron syndrome observation adds a genuinely fascinating scientific wrinkle: people with complete IGF-1 deficiency (Laron syndrome) have near-complete resistance to cancer and appear to live longer on average. This directly challenges the narrative that maximising IGF-1 is an anti-ageing strategy — it suggests that lower IGF-1 may be protective from a longevity standpoint, while higher IGF-1 is protective from a frailty/muscle-loss standpoint. These may be fundamentally incompatible goals.
For the performance user: the anabolic effects are real, the risks are real, and the safety data for healthy human use is essentially absent. For the anti-ageing user: the relationship between IGF-1 and longevity is complex enough that "more is better" is not a defensible position. The honest advice is to optimise endogenous IGF-1 through exercise, sleep, and adequate nutrition before considering exogenous sources.